Reevaluating the role of interferon‐beta in psoriasis pathogenesis: A registry‐based self‐controlled study
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17338 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Ida M Heerfordt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Psoriasis, Registries, Interferon-beta, Multiple Sclerosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interferon‐beta has been suggested as a trigger of psoriasis, yet a systematic investigation is lacking. This study aimed to assess the risk of developing psoriasis following interferon‐beta treatment, utilizing a pharmaco‐epidemiological approach to investigate the role of interferon‐beta in psoriasis pathogenesis. We included all treatment‐naïve patients with multiple sclerosis (MS) in Denmark who initiated interferon‐beta treatment for MS from January 1996 to June 2023. These patients were compared to a control cohort of patients with MS treated with other disease‐modifying drugs. We compared the incidence rates of psoriasis before and during the treatment. Data for this study were extracted from the Danish MS Registry and integrated with information from other national Danish health registries. Among 7174 patients treated with interferon‐beta, the incidence rate of psoriasis post‐treatment initiation was slightly higher (2.01 per 1000 person‐years) compared to the rate prior to treatment (1.67 per 1000 person‐years). This increase did not achieve statistical significance ( P = 0.53), with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 0.68–2.13). The control cohort showed an increase in psoriasis incidence post‐treatment initiation (3.12 per 1000 person‐years) compared to prior (1.11 per 1000 person‐years), with an IRR of 2.80 (95% CI 1.36–4.77, P = 0.0038). This registry‐based self‐controlled study does not support the theory that interferon‐beta acts as a trigger for psoriasis development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Dermatology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
ORCID-Profile: Ida M Heerfordt
Zitieren
APA
Heerfordt, I. M., Framke, E., Windfeld-Mathiasen, J., Mogensen, M., Olsen, R. H., Magyari, M., & Horwitz, H. (2024). Reevaluating the role of interferon‐beta in psoriasis pathogenesis: A registry‐based self‐controlled study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17338
Vancouver
Heerfordt IM, Framke E, Windfeld-Mathiasen J, Mogensen M, Olsen RH, Magyari M, et al. Reevaluating the role of interferon‐beta in psoriasis pathogenesis: A registry‐based self‐controlled study. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17338
BibTeX
@article{Heerfordt2024,
author = {Heerfordt, Ida M and Framke, Elisabeth and Windfeld-Mathiasen, Josefine and Mogensen, Mette and Olsen, Rasmus Huan and Magyari, Melinda and Horwitz, Henrik},
title = {Reevaluating the role of interferon‐beta in psoriasis pathogenesis: A registry‐based self‐controlled study},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17338}
}
EUVIMED